Review of NICE Technology Appraisal Guidance No 34; Trastuzumab for the treatment of advanced breast cancer

We originally anticipated this guidance would be included in the Clinical Guideline 81 – breast cancer (advanced). The Clinical Guideline did not update the guidance and therefore it has been returned for a reassessment of whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate the guidance be updated. 

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation. 

Please note all comments received will be published on the Institute’s website when a decision has been made.

12 June 2009